Lipiflow® is FDA approved for the treatment of Meibomian Gland Disease/Dysfunction (MGD). MGD is the root cause of most dry eye and its symptoms. Lipiflow®’s Vectored Thermal PulseTM technology applies simultaneous heat and pressure to the eyelid to remove gland contents and obstructions. A single-use sterile activator directs heat and pulsed pressure to target the meibomian glands during a 12-minute in-office procedure.
Meibomian Gland Disease/Dysfunction is chronic in that there is no cure. MGD must be treated and managed throughout the life of the patient. It is progressive in that those that are pre-symptomatic or not experiencing symptoms will develop them, while those that do experience symptoms will worsen over time without treatment. MGD is obstructive as solid-state lipids and dead cells block gland openings, preventing gland expression during blinking. It is this lack of gland stimulation that leads to gland death as they dilate (thicken), truncate (shorten), and atrophy (die).
Learn more about Dry Eye Syndrome and Meibomian Gland Disease/Dysfunction.